Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2023)
29 slides from Cocrystal Pharma's investor presentation, Jan 9, 2023
Slide 1: Potent antivirals to combat some of the most serious diseases facing humanity
Slide 2: Forward-Looking Statements
Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets « Pandemic and seasonal influenza A ¢ Pandemic SARS-CoV-2, SARS-CoV-2 variants, and coronaviruses °N i t teriti ppl inciomenuleroeretin, orovirus gastroenteritis drug discovery platform Drug candidates with clinically val
Slide 4: Investment Highlights
Investment Highlights e Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases e Proprietary drug discovery platform technology e Advancing multiple clinical programs e Oral influenza PB2 inhibitor, CC-42344 — Phase 1 completed and Phase 2a to begin H2 2
Slide 5: Pipeline Addressing Unmet Medical Needs
>; Pipeline Addressing Unmet Medical Needs al Phase 1 Phase 2 CC-42344 oral Planned Phase 2a trial Influenza A PB2 Inhibitor 7” initiation in H2 2023 Influenza A/B 5 » & Collaboration update Influenza A/B inhibitor In collaboration with > es MERCK P expected in H1 2023 CC-42344 Planned Phase 1 trial
Slide 6: Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals
Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select Drug Hit-to-lead Lead P F . x-ray crystals —_ binding pocket process optimizatio
Slide 7: Pandemic and Seasonal Influenza A Program
Pandemic and Seasonal Influenza A Program
Slide 8: Pandemic and Seasonal Influenza: A Major Global Health Concern
Pandemic and Seasonal Influenza: A Major Global Health Concern ° 1 billion cases’, 3-5 million severe illnesses? and up to 650,000 deaths" worldwide annually * Global influenza therapeutics market size is projected to reach $9.5 billion by 2027, from $6.6 billion in 2020, growing at a 4.8% CAGR betw
Slide 9: Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication
Cap Binding (PB2), Endonuclease (PA), and Polymerase (PB1) are Essential for Influenza Viral Replication Trimeric RNA Polymerase Complex Nucleus Cytoplasm PB1 y | » Viral RNA elF4E Translation Host pre-mRNA (~~ 4~ Chimeric RNA ? \ Wr 7-n~ 4 I IVS~ QS ~~ nn a SN “Cap snatching” ons AAA Ribosome <r co
Slide 10: CC-42344: Pandemic and Seasonal Influenza A Therapeutic and Prophylactic
CC-42344: Pandemic and Seasonal Influenza A Therapeutic and Prophylactic * Potent anti-influenza structure-based inhibitor Pandemic and seasonal influenza A PB2 crystals (H1N1, H2N2, H3N2, HSN1, and H7N9) * Binds a highly conserved region of influenza A PB2 of polymerase complex (PA:PB1:PB2) CC-4234
Slide 11: Phase 1 Study Completed
344 Phase 1 Study Completed Phase 1 trial site: Linear Clinical Research-Harry Perkins Research Institute , Perth, Australia icip ; Single-center, randomized, double-blind, placebo-controlled Single dose, multiple dose; 7-day nontreatment follow-up period Healthy adult volunteers Each cohort compris
Slide 12: Oral PB2 Inhibitor: Phase 1 Key Entry Criteria
Oral PB2 Inhibitor: Phase 1 Key Entry Criteria * Healthy males and females 2 18 and < 55 years ° Body weight 2 50 kg ° Body mass index 2 18 and s 32 kg/m2 * Non-pregnant, non-lactating * Must abstain from alcohol or caffeine from 48 hours before study confinement through study ° Must not have taken
Slide 13: CC-42344 Oral PB2 Inhibitor: Phase 1 Study Summary and Next Steps
CC-42344 Oral PB2 Inhibitor: Phase 1 Study Summary and Next Steps * Phase 1 study healthy volunteer study completed: Database lock pending * No serious AEs reported * Phase 2a human challenge study planned in H2 2023 * CRO: hVIVO, Queen Mary’s Bioenterprise Centre, London, UK ° Study design: randomi
Slide 14: Human bronchial airway epithelia infection data
Uninfected human bronchial airway epithelia 14 Influenza A H1N1 infection Gells-are-killed. by HINT virus, and, “mest cilia are destroyed Favorable safety profile: No toxicity in CC-42344- treated human lung epithelium Showed potent antiviral activity in influenza A (H1N1)-infected human lung epithe
Slide 15: Influenza A/B Program with Merck
Influenza A/B Program with € MERCK
Slide 16: Collaboration Validates Technology with Potential for Lucrative Returns
Collaboration Validates Technology with Potential for Lucrative Returns * Broad-spectrum, potent candidates developed to be active against seasonal, pandemic and existing drug-resistant influenza A and B strains * Announced exclusive worldwide license and collaboration with Merck in January 2019 Coc
Slide 17: SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
SARS-CoV-2 and SARS-CoV-2 Variants, and other Coronaviruses
Slide 18: Significant Need for New Antivirals to Combat Coronavirus Infections
Significant Need for New Antivirals to Combat Coronavirus Infections e Merck's molnupiravir and Pfizer's paxlovid (nimatrevir plus ritonavir) received FDA emergency use authorization; Shionogi’s Ensitrelvir received emergency regulatory approval in Japan e Coronaviruses constantly change through mut
Slide 19: Oral Main (3CL) Protease and Replication Inhibitors
Oral Main (3CL) Protease and Replication Inhibitors SARS -CoV-2 Infected cell Membrane f fusion Replication inhibitor mee | Endocytosis Release Uncoating Non-structural Structural RNA Polyproteins Q @) Translation Proteolysis «) = —@ Main (3CL) protease inhibitor 19 C®CRYSTAL - a
Slide 20: Highly conserved Cys144 residue across coronaviruses
SAR SARS_CoV-2_COVID19 SARS-CoV-1_POC6U8 MERS_K9N638 HKU1-N1_POC6U3 0c43_Poc6u7 229E_POc6U2 NL63_POC6U6 SFPANGEICGS| Biriticsr| ITIfcs rificsr| icsF| ing? TRISSFEING| GSFNGHCG Siac Highly conserved Cys144 residue ‘S$-CoV-2 SARS-CoV-1 eat ey MERS
Slide 21: CDI-988: Pandemic COVID-19 Oral Main (3CL) Protease Inhibitor
CDI-988: Pandemic COVID-19 Oral Main (3CL) Protease Inhibitor SARS-CoV-2 main protease (1.8 A) SARS-CoV-1 main protease (1.56 A) MERS-CoV main protease (1.9 A) CDI-988 oral inhibitor » Binds to a highly conserved, essential residue (Cys145) of SARS-CoV-2 main (3CL) protease and other coronavirus mai
Slide 22: Clinical Trial Design for COVID-19 Protease Inhibitors
Clinical Trial Design for COVID-19 Protease Inhibitors e Planned Phase 1 trial with lead candidate orally administered CDI-988 e Randomized, placebo-controlled, double-blind, single-ascending dose/multiple-ascending dose trial e Conducted in healthy volunteers in Australia « Evaluate safety, tolerab
Slide 23: Norovirus Gastroenteritis Program
Norovirus Gastroenteritis Program
Slide 24: Norovirus: Large Market with No Approved Treatments
Norovirus: Large Market with No Approved Treatments * Highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea * Major cause of gastrointestinal illness in closed and crowded environments including hospitals, nursing homes, childcare
Slide 25: Developing Broad-Spectrum Norovirus Protease and Replication Inhibitors
Developing Broad-Spectrum Norovirus Protease and Replication Inhibitors ° Broad-spectrum norovirus protease and replication inhibitors are being developed * Ongoing drug discovery efforts ° Oral protease inhibitor discovery using its proprietary drug discovery platform technology ° Preclinical evalu
Slide 26: Seasoned Leadership
easoned Leadership Sam Lee, Ph.D. Interim Co-Chief Executive Officer & Roger Kornberg, Ph.D. + Professor - President . . Chairman of the Board, Chairman of the Stanford University School of Medicine IcOos if js . 25+ years of anti-infective drug Scientific Advisory Board Nobel Laureate discovery res
Slide 27: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus * Issued patents in U.S. and major countries * Issued patents in U.S. and major countries * Pending U.S. provisional applications * Pending U.S. provisional applications Pandemic Influenza A HCV * PB2 (influenza A inhibitor) NS5B (NNI)
Slide 28: Financial Snapshot
Financial Snapshot ~$17 Million 44,000 Average 3 month MEINE GElp daily share volume’ 8.2 Million Fully diluted shares Clean balance sheet No preferred shares No debt Cash sufficient to fund planned operations 1 Yahoo Finance (January 3, 2023) 28 C@CRYSTAL
Slide 29: Investment Highlights
Investment Highlights e Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases e Proprietary drug discovery platform technology e Advancing multiple clinical programs e Oral influenza PB2 inhibitor, CC-42344 — Phase 1 completed and Phase 2a to begin H2 2
Cocrystal Pharma — Investor Presentation (January 2023) on 6ix